AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9459225
Drug: Lidocaine bolus
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine bolus (1.5 mg/kg) and infusion (3 mg/min, unless weight <70 kg, then 2 mg/min)
Trial: 2403850
Drug: succinylcholine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 0.15 mg.kg‐1
Trial: 2403850
Drug: succinylcholine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 0.25 mg.kg‐1
Trial: 2403850
Drug: succinylcholine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 0.50 mg.kg‐1
Trial: 2403850
Drug: succinylcholine 1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 1.00 mg.kg‐1
Trial: 2403850
Drug: succinylcholine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine (various doses)
Trial: 734314
Drug: Indomethacin, 100
RxNorm normalized name: Indomethacin, 100 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 100 mg orally
Trial: 734314
Drug: Prednisolone, 5
RxNorm normalized name: PrednisoLONE, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 5 mg
Trial: 26797810
Drug: Hydronidone 15-120
RxNorm normalized name: hydrocodone bitartrate 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydronidone 15-120 mg single dose
Trial: 26797810
Drug: Hydronidone 90
RxNorm normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydronidone 90 and 120 mg thrice daily for 7 days
Trial: 26797810
Drug: Hydronidone 60
RxNorm normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydronidone 60 mg thrice daily for 28 days
Trial: 26797810
Drug: Hydronidone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydronidone (all doses)
Trial: 25385061
Drug: topical artificial
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical artificial tear substitute (placebo)
Trial: 19470311
Drug: Immediate Treatment
RxNorm normalized name: Aquaphor Immediate Relief Lip Balm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Treatment group (7 clinic visits across 18 months)
Trial: 19470311
Drug: Delayed Treatment
RxNorm normalized name: GRANULES, DELAYED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Treatment group (9 clinic visits across 24 months)
Trial: 15570076
Drug: FOLFOX4 (LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 (LV and FU plus oxaliplatin 85 mg/m2 IV over 2 hours on day 1)
Trial: 15570076
Drug: LV5FU2 (LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 (LV 200 mg/m2 IV and FU 400 mg/m2 IV bolus, followed by FU 600 mg/m2 IV over 22 hours on days 1 and 2)
Trial: 11234669
Drug: Tinzaparin (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin (175 anti‐Xa IU/kg) administered subcutaneously once daily for 10 days
Trial: 9087473
Drug: Alendronate (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (dose higher than 1 mg per day)
Trial: 7655702
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment with beta-agonists (unspecified dosage and duration)
Trial: 7655702
Drug: As-needed beta-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed beta-agonists (unspecified dosage and duration)
Trial: 7655702
Drug: Fenoterol (unspecified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (unspecified dosage)
Trial: 7655702
Drug: Salbutamol (unspecified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (unspecified dosage)
Trial: 1972850
Drug: roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 300 mg once a day
Trial: 1972850
Drug: erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erythromycin 500 mg twice a day
Trial: 28702451
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prone and supine (SIPS)
Trial: 19025625
Drug: Dynamic arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic arterial line pressure (DALP) based prescription of Qb (300-500 mL/min)
Trial: 16189075
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen (trimethoprim, sulfamethoxazole, doxycycline, and chloramphenicol)
Trial: 16189075
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen (trimethoprim-sulfamethoxazole and doxycycline)
Trial: 30403937
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen
Trial: 16189075
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of oral therapy
Trial: 12651645
Drug: Clonidine 5
RxNorm normalized name: apraclonidine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 5 micro g/kg
Trial: 10651656
Drug: Pentasa 1
RxNorm normalized name: Pentasa 10 MG/ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa 1 g sachet (unit dose, microgranules in a foil bag)
Trial: 10651656
Drug: Pentasa 500
RxNorm normalized name: Pentasa 500mg Extended-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentasa 500 mg tablets (2 x 500 mg)
Trial: 2254831
Drug: 0.04% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04% CHX daily home marginal irrigation + 0.12% CHX professional irrigation
Trial: 2254831
Drug: Water daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water daily home marginal irrigation + 0.12% CHX professional irrigation
Trial: 2254831
Drug: Water daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water daily home marginal irrigation + water professional irrigation
Trial: 6104554
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg 3 times a day)
Trial: 531563
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg twice daily)
Trial: 6104554
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg 3 times a day)
Trial: 6104554
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg 3 times a day)
Trial: 26152568
Drug: Multifaceted feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted feedback strategy (extensive monthly feedback reports, outreach visits, quality improvement team)
Trial: 21890092
Drug: Nesiritide infusions
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide infusions
Trial: 19218044
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA), 40 mg twice daily for 2 months
Trial: 15310997
Drug: Dutasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (5 mg per day for 6 to 10 weeks)
Trial: 9663367
Drug: Venlafaxine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (200 mg/d)
Trial: 29097299
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (100mg daily)
Trial: 24074852
Drug: Change from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change from post-treatment through follow-up
Trial: 21072246
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (OZ)
Trial: 21072246
Drug: Oseltamivir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir plus inhaled placebo (O)
Trial: 21072246
Drug: Zanamivir plus
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir plus oral placebo (Z)
Trial: 18990048
Drug: Integrated acupuncture,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated acupuncture, tuina, and rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks (Group I)
Trial: 18990048
Drug: Rehabilitation (physiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks followed by acupuncture and tuina for 12 weeks (Group II)
Trial: 18990048
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (both groups)
Trial: 9417514
Drug: Fluconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (100 mg/d)
Trial: 1308663
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg/d)
Trial: 31310160
Drug: Long-term methimazole
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term methimazole therapy (60-120 months)
Trial: 31310160
Drug: Conventional methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional methimazole therapy (18-24 months)
Trial: 22924638
Drug: FFR-guided PCI
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR-guided PCI plus the best available medical therapy
Trial: 22924638
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available medical therapy alone
Trial: 22924638
Drug: Registry patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Registry patients (best available medical therapy)
Trial: 19330342
Drug: EE/CA-metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/CA-metformin
Trial: 19394976
Drug: metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin alone
Trial: 9689432
Drug: Nutrient-mixture (Aminoleban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrient-mixture (Aminoleban EN) 100 g/day for 2 to 6 weeks
Trial: 2777728
Drug: Intravenous gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gentamicin and 12 g/day piperacillin
Trial: 2777728
Drug: Intravenous gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gentamicin and 8 g/day piperacillin
Trial: 2777728
Drug: Intravenous gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gentamicin and piperacillin (both doses)
Trial: 2777728
Drug: Further antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further antibiotics added to unresponsive patients
Trial: 28814835
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of atorvastatin (Atorva®) 20 mg once daily
Trial: 28814835
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of atorvastatin (Lipitor®) 20 mg once daily
Trial: 18823024
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (G) alone
Trial: 12820466
Drug: Intraarterial continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day
Trial: 12820466
Drug: Bolus of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of cisplatin (CDDP), 24 mg/m2/day
Trial: 12820466
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms received i.v. escalating doses of fluorouracil
Trial: 8839635
Drug: New delayed-release
RxNorm normalized name: bisacodyl Delayed Release Oral Tablet [Correct (New Formula)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New delayed-release formulation of UDCA
Trial: 8839635
Drug: Traditional pH-dependent
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional pH-dependent sequential release formulation of UDCA
Trial: 6421010
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg buccal nitroglycerin
Trial: 6421010
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg buccal nitroglycerin
Trial: 6421010
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg buccal nitroglycerin
Trial: 6421010
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg sublingual nitroglycerin
Trial: 28196503
Drug: G-MISS questionnaire
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-MISS questionnaire
Trial: 22822451
Drug: NuFit active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuFit active blend (2.25 g leucine and 30 mg pyridoxine)
Trial: 19535190
Drug: Nicorandil, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil, 15 mg/d
Trial: 14673047
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus chemotherapy (cisplatin 80 mg/m2 x 1 day and fluorouracil 800 mg/m2 x 5 days)
Trial: 1610576
Drug: Methohexital anesthesia
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital anesthesia (0.5 to 1.0 mg/kg) with atropine premedication
Trial: 1610576
Drug: Methohexital anesthesia
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital anesthesia (0.5 to 1.0 mg/kg)
Trial: 6148881
Drug: Nadolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (80 to 320 mg for 6 weeks)
Trial: 31517543
Drug: Child STEPs
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child STEPs treatment program
Trial: 30845320
Drug: Vi-Typhoid Conjugate
RxNorm normalized name: typhoid Vi polysaccharide vaccine, S typhi Ty2 strain
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Trial: 30845320
Drug: Meningococcal serogroup
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal serogroup A conjugate vaccine (control)
Trial: 29524194
Drug: Low-Se diet
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Se diet (−Se group, 0.033 mg/kg Se)
Trial: 29524194
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet (control group, 0.2 mg/kg Se)
Trial: 17159195
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg intravenously every 6 months)
Trial: 16371734
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment and selective ERCP +/‐ ES after 48 hours
Trial: 23339958
Drug: Warfarin vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin vs Aspirin
Trial: 1295122
Drug: Nitrendipine (Nidrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (Nidrel 20 mg) administered once daily in the morning
Trial: 1295122
Drug: Nitrendipine (Nidrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (Nidrel 20 mg) administered once daily in the evening
Trial: 1295122
Drug: Nitrendipine (Nidrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (Nidrel 20 mg) administered once daily (both morning and evening)
Trial: 29458218
Drug: Curcuminoids plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids plus piperine (500 mg/day curcuminoids and 5 mg/day piperine)
Trial: 24121756
Drug: TMC310911 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 75 mg bid
Trial: 24121756
Drug: TMC310911 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 150 mg bid
Trial: 24121756
Drug: TMC310911 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 300 mg bid
Trial: 24121756
Drug: TMC310911 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 300 mg qd
Trial: 23145859
Drug: Ceftazidime-avibactam 500
RxNorm normalized name: avibactam
DrugBank: Avibactam (DB09060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime-avibactam 500 mg plus avibactam 125 mg every 8 hours for 7-14 days
Trial: 23145859
Drug: Imipenem-cilastatin 500
RxNorm normalized name: imipenem-cilastatin 500 mg-500 mg injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin 500 mg every 6 hours for 7-14 days
Trial: 21030934
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) for secondary prevention
Trial: 21030934
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) for primary prevention
Trial: 21030934
Drug: Consideration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consideration of ASA prescription
Trial: 18572751
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 10 mg/day
Trial: 2044551
Drug: Anistreplase (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anistreplase (30 U intravenous injection over 2-5 minutes)
Trial: 2044551
Drug: Streptokinase (1,500,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (1,500,000 U intravenous infusion over 60 minutes)
Trial: 7025638
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 mg, 5 mg every 12 hours, intramuscularly)
Trial: 27916480
Drug: A1 proteinase
RxNorm normalized name: Human alpha1 proteinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A1 proteinase inhibitor (A1PI) treatment (60 mg/kg per week)
Trial: 24627921
Drug: Restricted intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted intravenous fluid regimen (R group)
Trial: 16645442
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at the rate of 1-8 mug . kg . min for 15-20 min
Trial: 12965108
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg t.i.d. for 16 weeks
Trial: 10907674
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 100 mg)
Trial: 8836952
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg melatonin
Trial: 16263827
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg melatonin
Trial: 8836952
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg melatonin
Trial: 8836952
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg melatonin
Trial: 6438674
Drug: Diazepam (Valium)
RxNorm normalized name: diazepam Oral Tablet [Valium]
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (Valium) administration
Trial: 29469177
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion (24 hours)
Trial: 24758641
Drug: Delayed oocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oocyte maturation trigger (24 hours later) in patients with low progesterone (<= 1 ng/ml)
Trial: 24758641
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same day trigger) in patients with low progesterone (<= 1 ng/ml)
Trial: 24758641
Drug: Delayed oocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oocyte maturation trigger (24 hours later) in patients with elevated progesterone (> 1 ng/ml)
Trial: 24758641
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same day trigger) in patients with elevated progesterone (> 1 ng/ml)
Trial: 20435234
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg
Trial: 25450709
Drug: Entecavir 0.5
RxNorm normalized name: entecavir 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg
Trial: 16630123
Drug: Concurrent R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent R-CHOP (6 courses of CHOP concurrently with rituximab)
Trial: 16630123
Drug: Sequential R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential R-CHOP (6 courses of CHOP followed by 6 courses of weekly rituximab)